<DOC>
	<DOCNO>NCT02701283</DOCNO>
	<brief_summary>The study objective demonstrate safety effectiveness Medtronic TAVR system measure rate all-cause mortality disable stroke two year noninferior SAVR treatment severe aortic stenosis subject low predict risk operative mortality SAVR .</brief_summary>
	<brief_title>Medtronic Transcatheter Aortic Valve Replacement Low Risk Patients</brief_title>
	<detailed_description>Multi-center , international , prospective , randomize , interventional , pre-market . Subjects randomize 1:1 basis either TAVR Medtronic TAVR system SAVR . Patients see pre post-procedure , discharge , 30 day , 6 month , 1 year , 18 month , annually 10 year</detailed_description>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>1 . Severe aortic stenosis , define follow : 1 . For symptomatic patient : Aortic valve area ≤ 1.0 cm2 ( aortic valve area index ≤ 0.6 cm2/m2 ) , OR mean gradient ≥ 40 mmHg , OR Maximal aortic valve velocity ≥ 4.0 m/sec transthoracic echocardiography 2 . For asymptomatic patient : Very severe aortic stenosis aortic valve area ≤1.0 cm2 ( aortic valve area index ≤0.6 cm2/m2 ) , AND maximal aortic velocity ≥ 5.0 m/sec , mean gradient ≥r60 mmHg transthoracic echocardiography , OR Aortic valve area ≤1.0 cm2 ( aortic valve area index ≤0.6 cm2/m2 ) , AND mean gradient ≥ 40 mmHg maximal aortic valve velocity ≥ 4.0 m/sec transthoracic echocardiography , AND exercise tolerance test demonstrate limited exercise capacity , abnormal BP response , arrhythmia OR Aortic valve area ≤ 1.0 cm2 ( aortic valve area index ≤ 0.6 cm2/m2 ) , AND mean gradient ≥ 40 mmHg , maximal aortic valve velocity ≥ 4.0 m/sec transthoracic echocardiography , AND leave ventricular ejection fraction &lt; 50 % . 2 . Documented heart team agreement low risk SAVR , low risk define predict risk mortality SAVR &lt; 3 % 30 day 3 . The subject treating physician agree subject return require postprocedure followup visit 1 . Any condition consider contraindication placement bioprosthetic valve ( e.g . subject indicated mechanical prosthetic valve ) . 2 . A known hypersensitivity contraindication follow adequately premedicated : 1. aspirin heparin ( HIT/HITTS ) bivalirudin 2. ticlopidine clopidogrel 3 . Nitinol ( titanium nickel ) 4. contrast medium 3 . Blood dyscrasia define : leukopenia ( WBC &lt; 1000 mm3 ) , thrombocytopenia ( platelet count &lt; 50,000 cells/mm3 ) , history bleed diathesis coagulopathy , hypercoagulable state . 4 . Ongoing sepsis , include active endocarditis . 5 . Any percutaneous coronary peripheral interventional procedure bare metal stent within 30 day prior randomization , drug elute stent perform within 180 day prior randomization . 6 . Multivessel coronary artery disease Syntax score &gt; 22 and/or unprotected leave main coronary artery . 7 . Symptomatic carotid vertebral artery disease successful treatment carotid stenosis within 10 week Heart Team assessment . 8 . Cardiogenic shock manifest low cardiac output , vasopressor dependence , mechanical hemodynamic support . 9 . Recent ( within 2 month Heart Team assessment ) cerebrovascular accident ( CVA ) transient ischemic attack ( TIA ) . 10 . Gastrointestinal ( GI ) bleed would preclude anticoagulation . 11 . Subject refuse blood transfusion . 12 . Severe dementia ( result either inability provide inform consent trial/procedure , prevents independent lifestyle outside chronic care facility , fundamentally complicate rehabilitation procedure compliance followup visit ) . 13 . Estimated life expectancy le 24 month due associate noncardiac comorbid condition . 14 . Other medical , social , psychological condition opinion investigator precludes subject appropriate consent adherence protocol require followup exam . 15 . Currently participate investigational drug another device trial ( exclude registry ) . 16 . Evidence acute myocardial infarction ≤ 30 day trial procedure due unstable coronary artery disease ( WHO criteria ) . 17 . Need emergency surgery reason . 18 . Subject pregnant breast feeding . 19 . Subject less legal age consent , legally incompetent , otherwise vulnerable Anatomical exclusion criterion : 20 . Preexisting prosthetic heart valve position . 21 . Severe mitral regurgitation amenable surgical replacement repair . 22 . Severe tricuspid regurgitation amenable surgical replacement repair . 23 . Moderate severe mitral stenosis amenable surgical replacement repair . 24 . Hypertrophic obstructive cardiomyopathy leave ventricular outflow gradient . 25 . Bicuspid aortic valve verify echocardiography , MDCT , MRI . 26 . Prohibitive leave ventricular outflow tract calcification . 27 . Sinus Valsalva diameter unsuitable placement selfexpanding bioprosthesis . 28 . Aortic annulus diameter &lt; 18 &gt; 30 mm . 29 . Significant aortopathy require ascend aortic replacement . For transfemoral transaxillary ( subclavian ) access : 30 . Access vessel mean diameter &lt; 5.0 mm Evolut 23R , 26R , 29R TAV , &lt; 6.0 mm patent LIMA , access vessel mean diameter &lt; 5.5 mm Evolut 34R TAV &lt; 6.0 mm patent LIMA , access vessel mean diameter &lt; 6 mm CoreValve 31 mm TAV .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>